When was MAXVAX Biotechnology founded?

MAXVAX Biotechnology was founded in 2016 and raised its 1st funding round 2 years after it was founded.

Where is MAXVAX Biotechnology located?

MAXVAX Biotechnology is headquartered in Lanzhou, China.

Is MAXVAX Biotechnology a funded company?

MAXVAX Biotechnology is a funded company, having raised a total of $84.8M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 2018.

When was the latest funding round of MAXVAX Biotechnology?

MAXVAX Biotechnology's latest funding was a $***** Series D round on Dec 2025, with participation from 3 investors. Its primary sector is Immunotherapy. In China, the Immunotherapy sector has seen $359M in funding in 2026 to date.

Where does MAXVAX Biotechnology rank among its competitors?

MAXVAX Biotechnology ranks 30th amongst 319 active competitors, of which 81 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Ascletis Pharma, which secured $108M in Feb, 2026.

Who are the top competitors of MAXVAX Biotechnology?

MAXVAX Biotechnology's top competitors include Tonix Pharma, Dynavax and HOOKIPA Pharma. Among them, Ascletis Pharma secured the most recent funding round in February, 2026.

MAXVAX Biotechnology - 2026 Company Profile, Team, Funding & Competitors

MAXVAX Biotechnology is a series D company based in Lanzhou (China), founded in 2016 by Dexiang Chen. It operates as a Developer of vaccines for infectious diseases. MAXVAX Biotechnology has raised $84.8M in funding from investors like Korea Investment Partners, Hankang Capital and Hillhouse. The company has 319 active competitors, including 81 funded and 81 that have exited. Its top competitors include companies like Tonix Pharma, Dynavax and HOOKIPA Pharma.

Company Details

Developer of vaccines for infectious diseases. It offers an adjuvant platform, recombinant protein expression platform, and mRNA platform for developing preventive and therapeutic vaccines for influenza vaccine, rabies vaccine, rotavirus vaccine, and herpes zoster vaccine.

Website: www.maxvax.cn
Email ID: *****@maxvax.cn
Phone Number: +86 **********

Key Metrics

Founded Year

2016

Location

Lanzhou, China

Stage

Series D

Total Funding

$84.8M in 7 rounds

Latest Funding Round

Series D, Dec 2025, $*****

Investors

Korea Investment Partners & 11 more

Ranked

30^th among 319 active competitors

Similar Companies

Tonix Pharma & 387 more

View MAXVAX Biotechnology's full profile

MAXVAX Biotechnology has raised a total funding of $84.8M over 7 rounds. Its first funding round was on Feb 2018. Its latest funding round was a Series D round on Dec 2025 for $*****. 3 investors participated in its latest round. MAXVAX Biotechnology has 12 institutional investors.

Here is the list of recent funding rounds of MAXVAX Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 2025	5337100	Series D	3577326	6397299	9492601	7139136
Jul 01, 2024	7935004	Series C	3263487	3558811	2538551	Qianhai Ark Asset Management & 1 more
Feb 23, 2024	6233555	Series C	6482560	7720070	6306909	Shenzhen Capital Group

Access funding benchmarks and valuations. Sign up today!

View details of MAXVAX Biotechnology's funding rounds and investors

The founders of MAXVAX Biotechnology is Dexiang Chen.

Here are the details of MAXVAX Biotechnology's key team members:

Dexiang Chen: Founder of MAXVAX Biotechnology.

View details of MAXVAX Biotechnology's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MAXVAX Biotechnology include Tonix Pharma, Dynavax and HOOKIPA Pharma. Here is the list of Top 10 competitors of MAXVAX Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	67/100
2nd	Dynavax 1996, Berkeley (United States), Acquired	Developer of products to prevent and treat infectious and inflammatory diseases and cancer	$73.9M	Care Capital, Axiom Venture Partners & 27 others	66/100
3rd	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	65/100
4th	HilleVax 2021, Boston (United States), Public	Developer of a vaccine for norovirus infection	$135M	Frazier Healthcare Partners, Perceptive Advisors ... & 12 others	64/100
5th	Ascletis Pharma 2011, Hangzhou (China), Public	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	64/100
6th	Sinovac 2001, Haidian (China), Acquired	Developer of vaccines against multiple infectious diseases	-	Vivo Capital, Sino Biopharmaceutical & 3 others	64/100
7th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	64/100
8th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, America’s Seed Fund ... & 3 others	62/100
9th	VBI Vaccines 2001, Cambridge (United States), Public	Developer of vaccines for the treatment of infectious diseases	$65.1M	RTW Investments, Perceptive Advisors & 7 others	61/100
10th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	61/100
30th	MAXVAX Biotechnology 2016, Lanzhou (China), Series D	Developer of vaccines for infectious diseases	$84.8M	Hillhouse, China Life Insurance & 10 others	54/100